A Phase 3 interventional study of Netarsudil ophthalmic solution 0.02% and Ripasudil hydrochloride hydrate ophthalmic solution 0.4% in Primary Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-02-27.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 6th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 12th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2020.
This study's enrollment of 245 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 35th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2020, is one of 43 in phase 3, and was the 122nd registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
Drug: Netarsudil ophthalmic solution 0.02%
1 drop ripasudil twice daily in the morning and evening in each eye.
Drug: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
Topical sterile ophthalmic solution Other Name: Rhopressa®
Also known as: Vehicle: Netarsudil ophthalmic solution
Other Name: Glanatec®
Intraocular Pressure (IOP)
Comparison of both groups mean diurnal IOP at Week 4 (Day 29). IOP will be measured by Goldmann applanation tonometry and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Mean diurnal IOP was calculated as the average of 3 IOP values across 09:00, 11:00 and 16:00 time points.
Time frame: 29 Days
IOP at Weeks 1 and 2
Mean diurnal IOP as measured in mmHg at each post-treatment visit.
Time frame: Day 8, Day 15
Mean Change IOP From Baseline at Days 8, 15, 29
Mean change from baseline in mean diurnal IOP as measured in mmHg at each post-treatment visit.
Time frame: Baseline (Day 1), Days 8, 15, 29
Recruitment took place at 27 clinic sites in Japan starting on 30Nov2020 with last subject last visit on 30July2021.
| Milestone | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Started | 122 | 123 |
| Completed | 118 | 120 |
| Not completed | 4 | 3 |
| Milestone | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Started | 121 | 122 |
| Completed | 117 | 119 |
| Not completed | 4 | 3 |
| Milestone | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Started | 122 | 123 |
| Completed | 118 | 120 |
| Not completed | 4 | 3 |
| Milestone | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Started | 122 | 123 |
| Completed | 118 | 120 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Comparison of both groups mean diurnal IOP at Week 4 (Day 29). IOP will be measured by Goldmann applanation tonometry and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Mean diurnal IOP was calculated as the average of 3 IOP values across 09:00, 11:00 and 16:00 time points.
| mmHg | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Intraocular Pressure (IOP) | 15.96 ± 0.157 | 17.71 ± 0.155 |
Mean diurnal IOP as measured in mmHg at each post-treatment visit.
| mmHg | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Mean diurnal IOP at Weeks 1 (Days 8) | 16.28 ± 0.143 | 17.87 ± 0.141 |
| Mean diurnal IOP at Weeks 2 (Days 15) | 16.02 ± 0.168 | 17.83 ± 0.166 |
Mean change from baseline in mean diurnal IOP as measured in mmHg at each post-treatment visit.
| mmHg | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Baseline IOP mean diurnal IOP | 20.475 ± 0.2510 | 20.830 ± 0.3198 |
| V4: Week 1 (Day 8) Change from Baseline | -4.341 ± 0.1603 | -2.814 ± 0.1397 |
| V5: Week 2 (Day 15) Change from Baseline | -4.601 ± 0.1728 | -2.852 ± 0.1759 |
| V6: Week 4 (Day 29) Change from Baseline | -4.653 ± 0.1701 | -2.983 ± 0.1622 |
Collected over Volunteered or solicited AEs were collected from the time the subject received the first dose of study medication until Week 4 (Day 29) or study discontinuation. Unresolved AEs at the time of study exit were followed with proper medical care until the event was considered resolved or stabilized, the subject was lost to follow-up, or another resolution to the event was identified.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | 0/122 (0%) | 0/122 (0%) | 73/122 (59.8%) |
| Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | 0/123 (0%) | 2/123 (1.6%) | 82/123 (66.7%) |
| Event | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Treatment-Emergent Serious Adverse Event (TE-SAE)General disorders | 0/122 | 2/123 |
| Infections and infestationsRespiratory, thoracic and mediastinal disorders | 0/122 | 1/123 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 0/122 | 1/123 |
| Event | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 67/122 | 77/123 |
| Eye irritationEye disorders | 7/122 | 7/123 |
| Age, Customized(Participants) | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | Total |
|---|---|---|---|
| Age Category — < 65 years | 63 | 60 | 123 |
| Age Category — >= 65 years | 59 | 63 | 122 |
| Sex: Female, Male(Participants) | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | Total |
|---|---|---|---|
| Female | 78 | 66 | 144 |
| Male | 44 | 57 | 101 |
| Race and Ethnicity Not Collected(Participants) | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Study Eye Diagnosis(Participants) | Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle | Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% | Total |
|---|---|---|---|
| Ocular Hypertension | 32 | 35 | 67 |
| Primary Open Angle Glaucoma | 90 | 88 | 178 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jul 2021, 7 months.
Results were first posted in Feb 2023, 1 year 7 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 7 months is below that.
Counting every sponsor, half of 49 studies reached it within 25 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil